No abstract

No abstract

In most cases, the death of neurons in certain parts of the brain is the defining feature of a condition that is classified as neurodegenerative. There have been studies conducted on both conventional and innovative drugs, however the results have shown that they only offer symptomatic advantages and come with a number of undesirable side effects. The finding of more potent compounds that can stop the pathophysiology of these diseases will be seen as a miracle in the present day. There is a wide variety of synthetic compounds accessible; nevertheless, these drugs may also create a broad range of additional health issues. As a consequence of this, scientists are looking to plants and other natural sources for the development of new medicines. In the practise of conventional medicine, it has been discovered that certain plants possess healing powers. The use of phytochemicals, which are produced from medicinal plants, may eventually replace the need for synthetic molecules. Numerous phytochemicals have been shown to be effective in the treatment of a wide range of diseases. This article discusses the potential therapeutic applications of plant-derived alkaloids for a number of neurodegenerative disorders (NDDs), including Alzheimer's disease (AD), Huntington's disease (HD), Parkinson's disease (PD), epilepsy, schizophrenia, and stroke. There are many different types of alkaloids that can be found in the plant kingdom. Some of these alkaloids include isoquinoline, indole, pyrroloindole, oxindole, piperidine, pyridine, aporphine, vinca, -carboline, methylxanthene, lycopodium, and erythrine byproducts. Alkaloids have a beneficial effect on the pathophysiology of these diseases because of their ability to act as muscarinic and adenosine receptor agonists, anti-oxidants, anti-amyloid and MAO inhibitors, acetylcholinestrase and butyrylcholinesterase inhibitors, an inhibitor of synuclein aggregation, dopaminergic and nicotine agonists, and NMDA antagonists.

No abstract

This article provides a concise summary of the recent developments that have been achieved in our comprehension of the asymmetric addition processes that are catalysed by native Cinchona alkaloids and their derivatives. This class of reactions includes cycloadditions, 1,4-adds, direct nucleophilic additions across carbon–oxygen or carbon–nitrogen double bonds, and direct nucleophilic additions across carbon–oxygen double bonds. Because of their capacity to catalyse the addition of a wide variety of functional groups to C9, many Cinchona alkaloids have been utilised in these processes as catalysts. These functional groups include amino, alkoxy, hydroxyl, amido, urea, and thiourea, among others. The importance of mechanical variables is emphasised in many different contexts. Additionally, the utilisation of adducts in future synthesis is sometimes broken down into its component steps. Ocimum basilicum was discovered to be mostly consisted of estragol (> 35.71 percent), (E)-ocimene (> 1.47 percent), trans-bergamotene (> 0.83 percent), a-cadinol (> 0.41 percent), eucalyptol (> 0.25 percent), and -caryophyllene (> 0.07 percent), whereas Ocimum sanctum is primarily composed of eucaly There is a greater concentration of chemical components in the leaves of Ocimum basilicum and Ocimum sanctum than there is in the actual inflorescence or flowers of the plant. The genetic distance between the two species was analysed in order to better understand the interspecies relationship, and the results showed that it was 2.86. The small difference in genetic makeup that exists between Ocimum basilicum and Ocimum sanctum is evidence that these two species are related to one another and share similar traits.

Background: Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus. Epalrestat, an aldose reductase inhibitor, has been approved for clinical therapy for diabetic peripheral neuropathic pain. In the present study, solid lipid-based nanoparticles are used for oral administration of epalrestat (E-SLN) and evaluated against diabetic neuropathic pain in a rat model. Method: Experimental diabetes in rats was induced by a single dose of streptozotocin (STZ) administration. The therapeutic efficiency of Epalrestat nanoparticles (0.25, 0.50, 1, and 5 mg/kg) in diabetic rats was studied. STZ induced diabetic rats were treated with different doses of E-SLN for 8 weeks. The nanoparticles were orally administered at a single dose in rats, and the various parameters related to peripheral neuropathy were evaluated and compared with the bare drug. The blood glucose level was estimated by standard glucometer, HbA1c, triglycerides, total cholesterol and liver function test (ALT and AST) were analysed by blood samples collected from retro-orbital plexus. Oxidative stress markers and Na+K+ATPase, TNF-α and IL-1β levels were measured in the homogenate of sciatic nerves. Behavioural tests were also performed by the hot plate method and tail-flick method. Result: E-SLN synthesized by the micro-emulsification method were 281±60 nm in size, and encapsulation efficacy was found to be 88±2%. Optimized E-SLN were characterized and found to be optimum in size, spherical shape, decent encapsulation efficiency, stable at acidic gastric pH, and suitable for oral delivery. E-SLNs did not significantly reverse the STZ-induced elevated blood glucose level (FBS and PPBS), HbA1c, triglycerides and total cholesterol but significantly improved TNF-α, IL-1β, and increased Na+K+ATPase levels, oxidative stress marker and alanine transaminase, aspartate transaminase in the treated rat group as compared to the diabetic group. Doses of E-SLN, i.e. 0.5, 1.0, 2.5, and 5 mg/kg, significantly increased the tail-flick latency time and hot plate response time in a dose-dependent manner compared to the diabetic group. Conclusion: Thus, it is suggested that E-SLN were equally effective and less hepatotoxic compared to the standard treatment of epalrestat. To the best of our knowledge, we, for the first time, propose the orally deliverable E-SLN that ameliorates STZ induced diabetes neuropathic pain effectively as compared to conventional epalrestat.

No abstract

A simple and facile way of using biogenic silver nanoparticles (BSNP) (10–20 nm) was developed for wound healing acceleration and suppression of wound infections. The BSNP were formulated in an ointment base, and the study to accelerate the wound healing process was conducted in a rat. The pH of the BSNP ointment, pH 6.8 ± 0.5, lies in normal pH range of the human skin, with good spreadability and diffusibility. The wound closure rate, as a percentage, was highest at day 3 for a BSNP ointment-treated wound at 22.77 ± 1.60%, while in an untreated control the rate was 10.99 ± 1.74%, for Betadine 14.73 ± 2.36% and for Soframycin 18.55 ± 1.37%, compared with day 0. A similar pattern of wound closure rate was found at days 7 and 11. The antibacterial activity of BSNP was evaluated against wound-infection-causing bacteria Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli by the agar diffusion method. The total bacterial counts in the wound area were enumerated by the colony forming unit method. The lowest number of bacterial counts was found in the BSNP-treated wound compared with the other groups. BSNP treatment at 7.5% concentration enhanced migration of fibroblasts in a scratch assay. These findings reveal BSNP as an efficient contrivance for wound healing acceleration and as an eco-friendly alternative therapeutic antimicrobial agent.